



# ASX Announcement

22 April 2021

## Invitation to Register for EuGeni Launch Webinar



The Board and Chief Executive Officer of Brisbane-based biotech company, AnteoTech Ltd (ASX: ADO) ("AnteoTech" or "the Company") invite shareholders and investors to join the live stream Webinar of the media and public launch of the EuGeni Reader and COVID-19 Rapid Diagnostic Test.

Hosted by journalist, commentator, and author Madonna King, you will hear the latest developments from AnteoTech in a short panel discussion with CEO Derek Thomson, Head of Life Science, Dr Charlie Huang and Head of Assay Development, Tek Ling.

Shareholders have the opportunity to submit questions for the panel during the registration process.

Anyone wishing to attend the webinar needs to register using the link below.

### Event Details

**Date:** Wednesday, 28 April 2021

**Time:** 11.00am

**Register:** <https://webcast.boardroom.media/anteotech-ltd/20210428/NaN607d0df857d2fa00190a1e9b>

This announcement has been authorised for release by the Board.

### For more information, please contact:

Friederike Graser, Communications Manager, AnteoTech Ltd: +61 (0) 7 3219 0085

Ben Jarvis, Six Degrees Investor Relations: +61 (0) 413 150 448

### ABOUT ANTEO GROUP – AnteoTech Ltd (ASX:ADO)

AnteoTech is a surface chemistry company with Intellectual Property ("IP") in its core technology product groups AnteoCoat™, AnteoBind™ and AnteoRelease™. The Company's purpose is to create shareholder value by identifying and solving important global industry problems by providing unique value-add solutions for its customers. Customers operate in the life sciences, diagnostics, energy and medical devices markets.

Follow AnteoTech on Twitter: <https://twitter.com/AnteoTech> or visit [www.anteotech.com](http://www.anteotech.com)

